Chicago Capital LLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Chicago Capital LLC lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,244 shares of the medical equipment provider’s stock after purchasing an additional 294 shares during the period. Chicago Capital LLC’s holdings in Intuitive Surgical were worth $13,009,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Creekmur Asset Management LLC raised its position in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares during the period. Ridgewood Investments LLC acquired a new stake in shares of Intuitive Surgical during the second quarter worth about $26,000. Able Wealth Management LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at approximately $28,000. Delos Wealth Advisors LLC lifted its holdings in Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 57 shares in the last quarter. Finally, LRI Investments LLC purchased a new position in Intuitive Surgical in the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 396 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $486.88, for a total transaction of $192,804.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,680,761.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 396 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $486.88, for a total transaction of $192,804.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,680,761.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The disclosure for this sale can be found here. Insiders sold a total of 51,656 shares of company stock valued at $24,700,644 in the last quarter. Insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ISRG shares. Stifel Nicolaus lifted their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. Morgan Stanley boosted their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Evercore ISI cut their price target on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research note on Friday, July 19th. The Goldman Sachs Group started coverage on Intuitive Surgical in a research report on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Finally, Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price objective for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Price Performance

Shares of ISRG traded down $4.87 during trading hours on Friday, reaching $471.82. 1,700,169 shares of the company’s stock traded hands, compared to its average volume of 1,518,588. The business’s fifty day simple moving average is $458.74 and its two-hundred day simple moving average is $417.98. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $493.97. The firm has a market capitalization of $167.35 billion, a price-to-earnings ratio of 85.17, a P/E/G ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the previous year, the firm posted $1.18 EPS. The company’s quarterly revenue was up 14.5% on a year-over-year basis. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.